Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 8/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | CACNA1H | O95180 | 3/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8214513 | 0.90 | KDM4E (0.60) | TRPV1KDM4EHSD17B10ALDH1A1POLB | |
| SCHEMBL8209283 | 0.87 | CACNA1H (0.61) | TRPV1KDM4EHSD17B10ALDH1A1POLB | |
| SCHEMBL8210883 | 0.86 | TRPV1 (0.67) | TRPV1CACNA1H | |
| SCHEMBL8210013 | 0.85 | TRPV1 (0.67) | TRPV1CACNA1HKMT2A | |
| SCHEMBL14263466 | 0.85 | TRPV1 (0.64) | TRPV1CACNA1H | |
| SCHEMBL14263414 | 0.83 | TRPV1 (0.65) | TRPV1CACNA1H | |
| SCHEMBL8200792 | 0.83 | TRPV1 (0.72) | TRPV1KDM4ECACNA1HLMNAMAPK1 | |
| SCHEMBL8213440 | 0.82 | TRPV1 (0.67) | TRPV1CACNA1H | |
| SCHEMBL8210598 | 0.82 | TRPV1 (0.58) | TRPV1KDM4EHSD17B10ALDH1A1TSHR | |
| SCHEMBL8202850 | 0.81 | TRPV1 (0.67) | TRPV1CACNA1H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080076750-A1 | Azetidinone Derivatives and Methods of Use Thereof | SCHERING CORPORATION | 2008-03-27 | — | — | US | disclosed |
| US-20080076750-A1 | Azetidinone Derivatives and Methods of Use Thereof | SCHERING CORPORATION | 2008-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076750-A1 | Azetidinone Derivatives and Methods of Use Thereof | LIPC, CES1, ZDHHC20 | TRPV1 438/4885KDM4E 445/4885HSD17B10 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.